ICLUSIG®

Intended for licensed healthcare professionals located in Switzerland.

ICLUSIG 10 Year - Because Tomorrows Matters Today

For adult patients with CML failing on one 2G TKI, ICLUSIG^® combines experience and data to improve their futures^1–3*

Ph+ CML

ICLUSIG is indicated in adult patients suffering from T315I-positive Philadephia-positive (Ph+) chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase), or Ph+ chronic myeloid leukemia (chronic phase, accelerated phase or blast phase) for whom a treatment with other c-abl tyrosine kinase inhibitors is not appropriate.¹

Also available
for your
patients with
Ph+ ALL

Ph+ ALL

ICLUSIG is indicated in adult patients suffering from T315I-positive Ph+ acute lymphoblastic leukemia, or Ph+ acute lymphoblastic leukemia for whom a treatment with other c-abl tyrosine kinase inhibitors is not appropriate.¹

*In PACE: 82% and 59% of CP-CML responders are estimated to maintain MCyR and MMR at 5 years, respectively (Kaplan-Meier estimates).² For patients with CP-CML, the probability
of survival at 2, 3, 4, and 5 years is estimated as 86.0%, 81.2%, 76.9%, and 73.3%, respectively.¹ In OPTIC: 48% of patients who received the 45-mg starting dose achieved MCyR
at 12 months;¹ the response-based dosing regimen resulted in a clinically manageable safety profile.³

Abbreviations: 2G, second generation; CML, chronic myeloid leukaemia; CP, chronic-phase; MCyR, major cytogenetic response; MMR, major molecular response; OPTIC, Optimizing Ponatinib Treatment In CP-CML; PACE, Ponatinib Ph+ ALL and CML Evaluation Phase 2; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia; TKI, tyrosine kinase inhibitor.

References: 1. ICLUSIG^® Professional Information, see www.swissmedicinfo.ch; 2. Cortes JE, et al. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393─404; 3. Cortes JE, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042─50.

All references are available upon request.

CH/ICLG/P/23/0021
Date of preparation: October 2023

If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/